Physician profile
Jim Littlejohn
NPI 1225036841
$3,123.53
in general payments reported to CMS, 2019-2025
28 companies · $527 in 2025
The $527 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $271 · 2021: $485 · 2022: $706 · 2023: $580 · 2024: $199 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $643.63 | 2019-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $386.55 | 2023-2025 | Gemtesa |
| Teleflex LLC | $374.16 | 2021-2025 | Urolift, Barrigel |
| Tolmar, INC. | $181.82 | 2023-2025 | Eligard, Jatenzo |
| Urovant Sciences INC | $175.58 | 2022 | |
| Coloplast Corp | $162.32 | 2022-2024 | Speedicath |
| Endo Pharmaceuticals INC. | $144.55 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $141.76 | 2020-2022 | |
| Antares Pharma, INC. | $126.02 | 2019-2022 | |
| Abbvie INC. | $98.50 | 2024-2025 | |
| Boston Scientific Corporation | $95.97 | 2022-2025 | General - Female Sui, Rezum Generator |
| Clarus Therapeutics INC. | $74.54 | 2021 | |
| Pfizer INC. | $65.76 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.85 | 2021-2022 | |
| Blue Earth Diagnostics | $59.84 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $53.26 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $44.28 | 2025 | Bard Urinary Drainage Bag |
| Kowa Pharmaceuticals America, INC. | $36.97 | 2022-2023 | Seglentis |
| Olympus America INC. | $28.39 | 2025 | Itind System |
| Merck Sharp & Dohme LLC | $26.53 | 2023 | Lynparza, Welireg, Keytruda |
| Ambu INC. | $23.25 | 2020 | |
| Progenics Pharmaceuticals, INC. | $22.71 | 2023 | Pylarify |
| Neotract INC. | $21.70 | 2020 | |
| Ethicon US, LLC | $16.11 | 2025 | Vistaseal, Surgicel Nu-Knit |
| Laborie Medical Technologies Corp. | $15.39 | 2025 | |
| Amgen INC. | $15.06 | 2019 | |
| Allergan, INC. | $13.12 | 2021 | |
| Myovant Sciences INC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Littlejohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.